e-learning
resources
London 2016
Wednesday, 07.09.2016
Lung cancer: therapeutic modalities, re-staging, and follow-up
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Checkpointinhibition in lung cancer – How to distinguish pseudoprogression from progressive disease
Achim Rittmeyer (Immenhausen, Germany), Achim Rittmeyer, Birgit Zwerger, Reinhardt Christian, Josef Rüschoff, Hans-Ulrich Schildhaus, Stefan Andreas
Source:
International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Session:
Lung cancer: therapeutic modalities, re-staging, and follow-up
Session type:
Poster Discussion
Number:
4844
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Achim Rittmeyer (Immenhausen, Germany), Achim Rittmeyer, Birgit Zwerger, Reinhardt Christian, Josef Rüschoff, Hans-Ulrich Schildhaus, Stefan Andreas. Checkpointinhibition in lung cancer – How to distinguish pseudoprogression from progressive disease. Eur Respir J 2016; 48: Suppl. 60, 4844
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Related content which might interest you:
Surgical treatment outcomes on early-stages of non-small-cell lung cancer
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
Lung cancer, has it changed in the last ten years?
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015
Progression vs. pseudo progression in the treatment of squamous NSCLC with nivolumab
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
ALK/EML4 translocation in non-squamous NSCLC and their predictors
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
PET-CT predictors of mediastinal dissemination in lung cancer
Source: International Congress 2014 – Outcome prediction and imaging in thoracic surgery
Year: 2014
Diagnosing lung cancer: Choosing the best for your patient
Source: International Congress 2015 – Developments in lung cancer diagnosis
Year: 2015
Does IASLC/ATS/ERS classification of lung adenocarcinoma impacts prognosis?
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Futile thoracotomy in lung cancer
Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts
Year: 2013
Lung cancer in women: What are particularities?
Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer
Year: 2014
Clinical and therapeutic characteristics of patients died due to radiation-induced pneumonitis
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015
Segmentectomy for second lung cancer after lobectomy
Source: Annual Congress 2013 –Oncological thoracic surgery
Year: 2013
Electrospray-mediated local chemotherapy of lung carcinoma in mice
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016
Improving survival for NSCLC patients in the national lung cancer audit
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015
Algorithm of preoperative N-staging of non-small cell lung cancer
Source: Annual Congress 2013 –Oncological thoracic surgery
Year: 2013
EBUS-TBNA for nodal restaging and relapse in lung cancer
Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours
Year: 2014
Predictors of lung cancer patients delay time in Serbia - a cross-sectional study
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Lung cancer after lymphoma: Disease characteristics, detection methods and clinical outcome
Source: Annual Congress 2013 –Other thoracic tumours, particular circumstances and rare cases
Year: 2013
Prognostic factors for survival in lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Safety and efficacy of erlotinib in patients with squamous cell lung cancer
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Completion pneumonectomy for lung cancer relapse after surgery- What is a real benefit?
Source: Annual Congress 2013 –Oncological thoracic surgery
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept